article thumbnail

HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage

DAIC

milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.

Medicare 104
article thumbnail

CMS Updates Medicare Coverage for AI-Coronary Plaque Analysis

DAIC

15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). tim.hodson Wed, 10/16/2024 - 12:36 Oct. The four contractors for the U.S.

CMS 52
article thumbnail

CDL Nuclear Technologies Launches New Mobile Cardiac PET/CT Trailer

DAIC

milla1cf Tue, 04/23/2024 - 16:03 April 23, 2024 — CDL Nuclear Technologies , a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer. CDL provides this service in compliance with all healthcare regulations.

article thumbnail

CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

DAIC

Centers for Medicare & Medicaid Services (CMS) have granted the company’s Paradise Ultrasound Renal Denervation system a Transitional Pass-through (TPT) payment. The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries.

CMS 40
article thumbnail

Medtronic Presents New Data, Clinical Milestones at CRT 2025

DAIC

tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.

article thumbnail

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

DAIC

The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C. Having access to a patient’s whole coronary picture, with both quantified plaque and physiology, is a game changer as a clinician. F.A.C.C. “The For more information: www.heartflow.com References: 1.

article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. 3 “We very much appreciate FDA’s breakthrough designation recognition of the bioadaptor technology,” continued Sirhan. Food and Drug Administration (FDA). of the U.S.